- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07410117
REGN7508 bij volwassen deelnemers voor preventie van kanker-geassocieerde trombose (ROXI-CAT-I)
Een fase 3, multicenter, gerandomiseerde, dubbelblinde, placebo-gecontroleerde studie om de werkzaamheid en veiligheid te beoordelen van REGN7508, een monoklonaal antilichaam tegen FXI, voor primaire profylaxe van kanker-geassocieerde trombose bij deelnemers met solide tumoren die kankerbehandeling ondergaan (ROXI-CAT-I)
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants.
The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Clinical Trials Administrator
- Telefoonnummer: 844-734-6643
- E-mail: clinicaltrials@regeneron.com
Studie Locaties
-
-
-
Tbilisi, Georgië, 0159
- Werving
- Institute of Clinical Oncology
-
Tbilisi, Georgië, 0186
- Werving
- Caucasus Medical Centre
-
Tbilisi, Georgië, 0144
- Werving
- Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
-
Tbilisi, Georgië, 0179
- Werving
- LTD Cancer Research Centre
-
Tbilisi, Georgië, 0179
- Werving
- JSC Evex Hospitals - Caraps Medline
-
Tbilisi, Georgië, 0102
- Werving
- American Hospital Tbilisi
-
Tbilisi, Georgië, 0112
- Werving
- Llc Todua Clinic
-
Tbilisi, Georgië, 0112
- Werving
- Israel Georgia Medical Research Clinic Helsicore
-
-
Adjara
-
Batumi, Adjara, Georgië, 6000
- Werving
- LTD High Technology Hospital Medcenter
-
-
Imereti
-
Kutaisi, Imereti, Georgië, 4600
- Werving
- Krystyna Kiel Oncology Center
-
-
-
-
-
Niigata, Japan, 951-8520
- Werving
- Niigata University Medical & Dental Hospital
-
-
Ehime
-
Tōon, Ehime, Japan, 791-0295
- Werving
- Ehime University Hospital
-
-
Gunma
-
Ōta, Gunma, Japan, 373-8550
- Werving
- Gunma Prefectural Cancer Center
-
-
Hyōgo
-
Akashi, Hyōgo, Japan, 673-8558
- Werving
- Hyogo Cancer Center
-
-
Kagawa-ken
-
Kita-gun, Kagawa-ken, Japan, 761-0793
- Werving
- Kagawa University Hospital
-
-
Kanagawa
-
Isehara-Shi, Kanagawa, Japan, 259-1193
- Werving
- Tokai University Hospital
-
-
Kyoto
-
Kyoto, Kyoto, Japan, 602-8566
- Werving
- University Hospital Kyoto Prefectural University of Medicine
-
-
Miyagi
-
Sendai, Miyagi, Japan, 980-8574
- Werving
- Tohoku University Hospital
-
-
Osaka
-
Chuo, Osaka, Japan, 540-0006
- Werving
- National Hospital Organization Osaka National Hospital (ONH)
-
-
Saitama
-
Ina-machi, Saitama, Japan, 362-0806
- Werving
- Saitama Cancer Center
-
-
Tokyo
-
Chuo Ku, Tokyo, Japan, 104-0045
- Werving
- National Cancer Center Hospital - Tsukiji Campus
-
Shinjuku, Tokyo, Japan, 160-0023
- Werving
- Tokyo Medical University Hospital
-
-
Yamaguchi
-
Ube, Yamaguchi, Japan, 755-8505
- Werving
- Yamaguchi University Hospital
-
-
-
-
Florida
-
Hialeah, Florida, Verenigde Staten, 33013
- Werving
- Bioresearch Partner- Hialeah Hospital
-
North Miami Beach, Florida, Verenigde Staten, 33169
- Werving
- Helios Clinical Research
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215
- Werving
- Beth Israel Deaconess Medical Center
-
-
New York
-
New York, New York, Verenigde Staten, 10021
- Werving
- Memorial Sloan Kettering Cancer Center
-
-
Texas
-
El Paso, Texas, Verenigde Staten, 79902
- Ingetrokken
- El Paso Medical Research Institute (Medresearch Inc)
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria:
- Has a histologically confirmed diagnosis of malignant solid tumors which are locally advanced or metastatic as described in the protocol
- Has a Khorana thromboembolic risk score ≥2 during screening period or harbors a somatic documented tumor genetic variant known to be associated with a similar increased risk of VTE as described in the protocol
- Has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2 at the time of screening and day 1 prior to the first dose of study intervention
Key Exclusion Criteria:
- Has known bleeding conditions (eg, Hemophilia A or B, von Willebrand's disease), hemorrhagic tumor sites, or other conditions with a high risk for bleeding (eg, hepatic disease associated with coagulopathy)
- Has a cancer diagnosis consisting solely of basal cell or squamous cell skin carcinoma
- Has a primary brain tumor or brain metastases as described in the protocol
- Has proximal lower extremity DVT locally detected by Compression Ultrasound (CUS) during screening period
- Has any condition that, as judged by the investigator, may confound the results of the study or would place the participant at increased risk of harm if he/she participated in the study
Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Placebo-vergelijker: Placebo
|
Administered per the protocol |
|
Experimenteel: REGN7508
|
Administered per the protocol
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Tijd tot eerste gebeurtenis van centraal beoordeelde International Society of Thrombosis and Hemostasis (ISTH) ernstige bloeding of klinisch relevante niet-ernstige (CRNM) bloeding
Tijdsspanne: Gedurende 6 maanden
|
Gedurende 6 maanden
|
|
Time-to-first event of centrally adjudicated VTE (DVT, PE) or ATE, or thromboembolism- or ATE-related death
Tijdsspanne: Through 6 months
|
Through 6 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Voorkomen van behandeling-gerelateerde bijwerkingen (TEAEs)
Tijdsspanne: Tot dag 245
|
Tot dag 245
|
|
Ernst van TEAE's
Tijdsspanne: Tot dag 245
|
Tot dag 245
|
|
Omvang van ADA tegen REGN7508
Tijdsspanne: Tot dag 245
|
Tot dag 245
|
|
Time-to-first event of the centrally adjudicated symptomatic or incidental VTE (DVT, PE) or ATE and thromboembolism- or ATE-related death
Tijdsspanne: Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic VTE
Tijdsspanne: Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic DVT
Tijdsspanne: Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic non-fatal PE
Tijdsspanne: Through 6 months
|
Through 6 months
|
|
Time-to-first event of thromboembolism-related death
Tijdsspanne: Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental VTE
Tijdsspanne: Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental upper extremity or incidental proximal lower extremity DVT
Tijdsspanne: Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental non-fatal PE (in a segmental or larger pulmonary artery)
Tijdsspanne: Through 6 months
|
Through 6 months
|
|
Time-to-first event of asymptomatic VTE (Asymptomatic DVT detected by lower extremities ultrasound)
Tijdsspanne: Through 6 months
|
Through 6 months
|
|
Time-to-first event of ATE
Tijdsspanne: Through 6 months
|
Through 6 months
|
|
Time-to-first event of ATE-related death
Tijdsspanne: Through 6 months
|
Through 6 months
|
|
Time-to-first event of centrally adjudicated VTE (DVT, PE), or thromboembolism-related death
Tijdsspanne: Through 6 months
|
Through 6 months
|
|
Occurrence of Anti-Drug Antibody (ADA) to REGN7508
Tijdsspanne: Up to day 245
|
Up to day 245
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Clinical Trial Management, Regeneron Pharmaceuticals
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- R7508-CAT-2392
- 2024-519298-21-00 (Ctis)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD-tijdsbestek voor delen
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD-toegangscriteria voor delen
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
- ANALYTIC_CODE
- MVO
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .